The role of IL-6 in host defence against infections: Immunobiology and clinical implications

Stefan Rose-John, Kevin Winthrop, Leonard Calabrese

Research output: Contribution to journalReview article

55 Citations (Scopus)

Abstract

IL-6 is a pleiotropic cytokine with broad-ranging effects within the integrated immune response. One of the roles of IL-6 is to support immunocompetence, defined as the ability of a host to respond to infections. Understanding the precise role of this cytokine in immunocompetence requires a critical appraisal of data derived from both preclinical and clinical studies. Primary immunodeficiency diseases involving IL-6 or its signalling pathways reveal that IL-6 is critical in the defence against numerous types of pathogens. Studies of IL-6 signalling in preclinical models reveal that selective inhibition of either classic IL-6 signalling or IL-6 trans-signalling has differential effects on the host response to different types of infections. Knowledge of such variation might inform bioengineering of new IL-6-targeting molecules and potentially enable modulation of their toxicity. Clinical studies of IL-6 inhibitors, mainly tocilizumab, reveal that their use is associated with an increased rate of both serious and opportunistic infections generally in the range observed with other non-IL-6 directed biologic therapies. Targeting IL-6 has several other important clinical implications related to diagnosis, management and prevention of infectious diseases.

Original languageEnglish (US)
Pages (from-to)399-409
Number of pages11
JournalNature Reviews Rheumatology
Volume13
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Interleukin-6
Infection
Immunocompetence
Cytokines
Bioengineering
Biological Therapy
Opportunistic Infections
Communicable Diseases

ASJC Scopus subject areas

  • Rheumatology

Cite this

The role of IL-6 in host defence against infections : Immunobiology and clinical implications. / Rose-John, Stefan; Winthrop, Kevin; Calabrese, Leonard.

In: Nature Reviews Rheumatology, Vol. 13, No. 7, 01.07.2017, p. 399-409.

Research output: Contribution to journalReview article

@article{a6d6e5ffc7ad47bebfe8fd2be3750b36,
title = "The role of IL-6 in host defence against infections: Immunobiology and clinical implications",
abstract = "IL-6 is a pleiotropic cytokine with broad-ranging effects within the integrated immune response. One of the roles of IL-6 is to support immunocompetence, defined as the ability of a host to respond to infections. Understanding the precise role of this cytokine in immunocompetence requires a critical appraisal of data derived from both preclinical and clinical studies. Primary immunodeficiency diseases involving IL-6 or its signalling pathways reveal that IL-6 is critical in the defence against numerous types of pathogens. Studies of IL-6 signalling in preclinical models reveal that selective inhibition of either classic IL-6 signalling or IL-6 trans-signalling has differential effects on the host response to different types of infections. Knowledge of such variation might inform bioengineering of new IL-6-targeting molecules and potentially enable modulation of their toxicity. Clinical studies of IL-6 inhibitors, mainly tocilizumab, reveal that their use is associated with an increased rate of both serious and opportunistic infections generally in the range observed with other non-IL-6 directed biologic therapies. Targeting IL-6 has several other important clinical implications related to diagnosis, management and prevention of infectious diseases.",
author = "Stefan Rose-John and Kevin Winthrop and Leonard Calabrese",
year = "2017",
month = "7",
day = "1",
doi = "10.1038/nrrheum.2017.83",
language = "English (US)",
volume = "13",
pages = "399--409",
journal = "Nature Reviews Rheumatology",
issn = "1759-4790",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - The role of IL-6 in host defence against infections

T2 - Immunobiology and clinical implications

AU - Rose-John, Stefan

AU - Winthrop, Kevin

AU - Calabrese, Leonard

PY - 2017/7/1

Y1 - 2017/7/1

N2 - IL-6 is a pleiotropic cytokine with broad-ranging effects within the integrated immune response. One of the roles of IL-6 is to support immunocompetence, defined as the ability of a host to respond to infections. Understanding the precise role of this cytokine in immunocompetence requires a critical appraisal of data derived from both preclinical and clinical studies. Primary immunodeficiency diseases involving IL-6 or its signalling pathways reveal that IL-6 is critical in the defence against numerous types of pathogens. Studies of IL-6 signalling in preclinical models reveal that selective inhibition of either classic IL-6 signalling or IL-6 trans-signalling has differential effects on the host response to different types of infections. Knowledge of such variation might inform bioengineering of new IL-6-targeting molecules and potentially enable modulation of their toxicity. Clinical studies of IL-6 inhibitors, mainly tocilizumab, reveal that their use is associated with an increased rate of both serious and opportunistic infections generally in the range observed with other non-IL-6 directed biologic therapies. Targeting IL-6 has several other important clinical implications related to diagnosis, management and prevention of infectious diseases.

AB - IL-6 is a pleiotropic cytokine with broad-ranging effects within the integrated immune response. One of the roles of IL-6 is to support immunocompetence, defined as the ability of a host to respond to infections. Understanding the precise role of this cytokine in immunocompetence requires a critical appraisal of data derived from both preclinical and clinical studies. Primary immunodeficiency diseases involving IL-6 or its signalling pathways reveal that IL-6 is critical in the defence against numerous types of pathogens. Studies of IL-6 signalling in preclinical models reveal that selective inhibition of either classic IL-6 signalling or IL-6 trans-signalling has differential effects on the host response to different types of infections. Knowledge of such variation might inform bioengineering of new IL-6-targeting molecules and potentially enable modulation of their toxicity. Clinical studies of IL-6 inhibitors, mainly tocilizumab, reveal that their use is associated with an increased rate of both serious and opportunistic infections generally in the range observed with other non-IL-6 directed biologic therapies. Targeting IL-6 has several other important clinical implications related to diagnosis, management and prevention of infectious diseases.

UR - http://www.scopus.com/inward/record.url?scp=85021014942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021014942&partnerID=8YFLogxK

U2 - 10.1038/nrrheum.2017.83

DO - 10.1038/nrrheum.2017.83

M3 - Review article

C2 - 28615731

AN - SCOPUS:85021014942

VL - 13

SP - 399

EP - 409

JO - Nature Reviews Rheumatology

JF - Nature Reviews Rheumatology

SN - 1759-4790

IS - 7

ER -